Compare ACADIA Pharmaceuticals Inc. (ACAD) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs VanEck Junior Gold Miners — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while VanEck Junior Gold Miners trades at $95.32. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| ACAD | GDXJ | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $28.06 | $156.19 |
52-Week Low | $20.06 | $64.22 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GDXJ trades at $103.91, up 0.97% today, with technical indicators showing mixed signals (neutral overall, bearish moving averages). The ETF faces headwinds from underperformance versus peers in 2026, with significant portfolio overlap and limited small-cap exposure. Recent news highlights silver price volatility and gold's rally near $4,700, affecting junior miner sentiment.
The outlook remains cautious due to Federal Reserve rate uncertainty and competitive pressures. Investment opportunities hinge on gold price sustainability, but risks include sector underperformance and macroeconomic sensitivity. Analyst sentiment is neutral to bearish, reflecting concerns over the ETF's strategic positioning and recent returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
